|
Patent landscape, scope, and claims: |
United States Drug Patent 7,232,572: Scope, Claims, and Landscape Analysis
United States Patent 7,232,572, granted on June 19, 2007, to Merck & Co., Inc., covers pyrazolo[3,4-d]pyrimidine compounds, their preparation, and their use in treating diseases mediated by phosphodiesterase (PDE) isoenzymes. The patent's claims are directed to novel chemical entities and their therapeutic applications, particularly for conditions involving PDE inhibition. The patent landscape for this specific compound class is characterized by the presence of major pharmaceutical innovators and ongoing research into PDE inhibitors for various indications.
What are the core claims of US Patent 7,232,572?
The primary claims of US Patent 7,232,572 define a genus of pyrazolo[3,4-d]pyrimidine compounds.
Claim 1 is representative and defines a specific structural formula:
-
A compound of formula (I):
R1
\
N--N
/ \
R2-C C-R3
|| //
N--C
/ \
R4 R5
wherein:
- R1 is selected from H, alkyl, and alkoxy;
- R2 is selected from substituted or unsubstituted aryl, heteroaryl, cycloalkyl, and alkyl;
- R3 is selected from substituted or unsubstituted aryl, heteroaryl, cycloalkyl, and alkyl;
- R4 is selected from H, alkyl, and alkoxy;
- R5 is selected from substituted or unsubstituted aryl, heteroaryl, cycloalkyl, and alkyl.
The patent further specifies various substituents for the aryl, heteroaryl, cycloalkyl, and alkyl groups, detailing potential functional groups that can be incorporated into the core structure. This broad definition encompasses a wide range of potential drug candidates.
Other key claims include:
- Pharmaceutical Compositions: Claims directed to pharmaceutical compositions comprising at least one compound of formula (I) and a pharmaceutically acceptable carrier. This extends protection to the formulation and delivery of the active pharmaceutical ingredients.
- Methods of Treatment: Claims covering methods of treating diseases mediated by PDE isoenzymes. This includes conditions such as inflammatory diseases, cardiovascular diseases, central nervous system disorders, and respiratory diseases. The patent enumerates specific PDE isoenzymes (e.g., PDE4, PDE5) and associated therapeutic outcomes.
- Specific Embodiments: The patent details numerous specific compounds falling within the scope of the general formula, often referred to as "exemplified compounds." These specific embodiments provide concrete examples of the claimed invention and are critical for establishing inventorship and enablement.
What is the therapeutic scope and intended use of the patented compounds?
The therapeutic scope of US Patent 7,232,572 is broad, focusing on diseases modulated by phosphodiesterase (PDE) enzymes. PDE enzymes are critical regulators of intracellular cyclic nucleotide levels (cAMP and cGMP), which play significant roles in various physiological processes. By inhibiting specific PDE isoenzymes, the compounds claimed in this patent aim to:
- Modulate Inflammatory Responses: Inhibition of PDE4, a major isoenzyme in inflammatory cells, can lead to increased intracellular cAMP levels, resulting in suppression of pro-inflammatory cytokine production and degranulation. This application is relevant for conditions like asthma, chronic obstructive pulmonary disease (COPD), and inflammatory skin diseases.
- Affect Cardiovascular Function: Inhibition of PDE5, prevalent in smooth muscle cells of the vasculature, can increase cGMP levels, leading to vasodilation. This has implications for treating erectile dysfunction and pulmonary arterial hypertension.
- Impact Central Nervous System (CNS) Activity: Certain PDE isoenzymes are found in the brain and are involved in neurotransmitter signaling and neuronal plasticity. Inhibition can be explored for neurodegenerative diseases, cognitive disorders, and psychiatric conditions.
- Influence Respiratory Conditions: Beyond inflammatory aspects, PDE inhibition can affect airway smooth muscle tone and mucus secretion, relevant for asthma and COPD management.
The patent explicitly mentions treating conditions such as inflammatory disorders, allergic diseases, cardiovascular diseases, neurological disorders, and oncological disorders where PDE activity plays a role.
How does US Patent 7,232,572 relate to marketed PDE inhibitors?
US Patent 7,232,572 covers a specific chemical class (pyrazolo[3,4-d]pyrimidines). While this patent might not directly claim all marketed PDE inhibitors, its scope is significant in the context of PDE research and development.
- Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra): These are well-known PDE5 inhibitors used for erectile dysfunction and pulmonary hypertension. Their chemical structures are generally based on a pyrazolo[4,3-d]pyrimidine core, which is structurally related but distinct from the pyrazolo[3,4-d]pyrimidine core claimed in US Patent 7,232,572. This distinction means that compounds like sildenafil are not directly covered by the primary claims of 7,232,572. However, the underlying research and understanding of pyrazolopyrimidine scaffolds in PDE inhibition is common.
- Roflumilast (Daliresp/Daxas): This is a PDE4 inhibitor used for COPD. Its chemical structure is based on a benzamide derivative, not the pyrazolo[3,4-d]pyrimidine core of 7,232,572.
- Apremilast (Otezla): Another PDE4 inhibitor, Apremilast has a distinct phthalimide-based structure.
The relevance of US Patent 7,232,572 lies in its foundational protection of a particular pyrazolopyrimidine scaffold for PDE inhibition. Companies developing PDE inhibitors within this specific chemical class would need to navigate potential infringement. Conversely, companies developing PDE inhibitors with different core structures are less likely to be impacted by the direct claims of this patent, though indirect impacts via freedom-to-operate analyses for related research areas are possible. The patent's expiration date is crucial for understanding when its core protections will enter the public domain.
What is the patent expiration timeline for US Patent 7,232,572?
US Patent 7,232,572 was granted on June 19, 2007. Under US patent law, the standard term of a utility patent is 20 years from the filing date, subject to maintenance fees.
- Application Filing Date: The earliest filing date associated with US Patent 7,232,572 appears to be May 28, 2002 (as a continuation-in-part application).
- Expiration Date: Therefore, the patent is expected to expire approximately 20 years from its filing date, placing its expiration around May 28, 2022.
It is important to note that patent term extensions (PTE) or adjustments may apply, particularly for pharmaceutical patents that experience significant regulatory review delays. However, based on the standard term, the core claims of US Patent 7,232,572 are no longer in force.
What is the competitive landscape for pyrazolo[3,4-d]pyrimidine PDE inhibitors?
The competitive landscape for pyrazolo[3,4-d]pyrimidine PDE inhibitors, particularly concerning the scope of US Patent 7,232,572, is shaped by several factors:
- Major Pharmaceutical Companies: Companies like Merck & Co., Inc. (the patent assignee), Pfizer Inc., GlaxoSmithKline plc, and others have historically invested heavily in PDE inhibitor research. Their patent portfolios often cover various structural classes and therapeutic applications.
- Academic Research: Universities and research institutions contribute significantly to the discovery of novel PDE inhibitors and mechanisms of action, often leading to early-stage patent filings that are subsequently licensed or acquired by pharmaceutical companies.
- Generic Competition Post-Expiration: With the expiration of US Patent 7,232,572, the chemical space defined by its core claims becomes available for generic manufacturers, provided no other valid patents (e.g., method of use patents, formulation patents) remain in force.
- Emerging Therapeutic Areas: The ongoing understanding of PDE isoenzyme roles in diseases beyond those initially targeted (e.g., neuroinflammation, metabolic disorders) continues to drive research and patent activity in this area.
- Patent Litigation: The history of PDE inhibitor patents is marked by significant patent litigation, often concerning infringement of method of use claims or challenges to patent validity.
While US Patent 7,232,572 itself has expired, the broader class of pyrazolopyrimidine compounds and their therapeutic uses remain an area of interest. Competitors would analyze the expiration dates of related patents and any subsequent patents filed by Merck or others covering specific compounds within this class, their improved formulations, or novel therapeutic applications to assess freedom-to-operate and market exclusivity.
What are the potential implications of patent expiration on market dynamics?
The expiration of US Patent 7,232,572 has several implications for market dynamics:
- Entry of Generic or Biosimilar Products: For any specific drug compound that was claimed by US Patent 7,232,572 and reached the market, its expiration paves the way for generic competition. This typically leads to a significant decrease in drug prices due to increased competition.
- Increased Research and Development: The public domain status of the patented chemical scaffold may encourage further research and development by other entities. New companies or research groups can now develop novel compounds based on this structure without infringing the expired patent.
- Market Competition Shift: The competitive landscape shifts from defending patent exclusivity to competing on product differentiation, cost-effectiveness, and novel therapeutic applications not covered by other active patents.
- Revival of Older Compounds: Expired patents can sometimes lead to a renewed interest in older, effective compounds that may have been overshadowed by newer, patented alternatives.
Given that the expiration date is likely in the recent past (around May 2022), the market impact would be observable through the launch of generic versions of any drugs falling within its original claims. Companies that held market exclusivity for such drugs would have experienced a decline in market share and revenue due to generic entry.
Key Takeaways
- US Patent 7,232,572 protects pyrazolo[3,4-d]pyrimidine compounds and their use in treating PDE-mediated diseases.
- The patent's claims are broad, covering a genus of chemical structures and their therapeutic applications, including inflammatory, cardiovascular, and CNS disorders.
- The patent expired around May 2022, based on its filing date of May 28, 2002, and its grant date of June 19, 2007.
- This expiration allows for the development and marketing of generic versions of any drugs falling within the expired patent's claims.
- While structurally related to some marketed PDE inhibitors (e.g., PDE5 inhibitors like sildenafil), the pyrazolo[3,4-d]pyrimidine core is distinct from the pyrazolo[4,3-d]pyrimidine core of drugs like sildenafil.
Frequently Asked Questions
-
Does the expiration of US Patent 7,232,572 mean all pyrazolo[3,4-d]pyrimidine drugs are now off-patent?
No. Patent expiration applies to the specific claims of that patent. Other patents covering specific compounds within the pyrazolo[3,4-d]pyrimidine class, novel formulations, or specific methods of use may still be in force, providing continued market exclusivity.
-
What is the difference between a pyrazolo[3,4-d]pyrimidine and a pyrazolo[4,3-d]pyrimidine scaffold?
These are isomeric structures where the positions of the nitrogen atoms and fused rings differ, leading to distinct chemical properties and biological activity profiles, even though they share common building blocks.
-
Can a company develop a new drug using the pyrazolo[3,4-d]pyrimidine scaffold now that the patent has expired?
Yes, a company can research and develop new compounds based on this scaffold. However, they must ensure their new compound and its intended use do not infringe on any other currently active patents held by Merck or other entities.
-
What are the typical maintenance fees associated with US drug patents like 7,232,572?
Maintenance fees are tiered and are due at 3.5, 7.5, and 11.5 years after the patent grant date. For a patent granted in 2007, these fees would have been paid to keep the patent in force until its expiration.
-
What is the role of the Patent Term Extension (PTE) for pharmaceutical patents?
PTE can extend the term of a patent to compensate for regulatory review delays (e.g., FDA approval process), up to a maximum of five years. Whether PTE applied to US Patent 7,232,572 would depend on specific regulatory submission and approval timelines.
Citations
[1] Merck & Co., Inc. (2007, June 19). Pyrazolo[3,4-d]pyrimidine compounds (U.S. Patent No. 7,232,572). United States Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [USPTO website for patent term calculation, specific URL is dynamic and depends on the tool used by USPTO]
More… ↓
⤷ Start Trial
|
